This surface-treated hydrotalcite is obtained by surface-treating a hydrotalcite having a compositional makeup represented by formula (1) and satisfies (A)-(C). This hydrotalcite has excellent dispersibility.

(M.sup.2+).sub.(1-x)(M.sup.3+).sub.x(OH).sub.2(A.sup.n−).sub.x/n.Math.mH.sub.2O  (1) (Wherein, respective signs in formula (1) are as defined in the claims.) (A) The proportion of a surface-treating agent is 20-50 mass %. (B) The average width of primary particles is 5-120 nm. (C) The monodispersity is 75% or more.

The present disclosure concerns mesoporous silica nanoparticles (MSNP) functionalized to cross in and out of cells and loaded with one or more therapeutics to provide a vehicle that can effectively provide localized treatment to both intracellular and extracellular space. The MSNPs provide a vehicle for adjunct treatment of periodontitis, being able to provide treatment against the microbes and to the tissue.

The present disclosure concerns mesoporous silica nanoparticles (MSNP) functionalized to cross in and out of cells and loaded with one or more therapeutics to provide a vehicle that can effectively provide localized treatment to both intracellular and extracellular space. The MSNPs provide a vehicle for adjunct treatment of periodontitis, being able to provide treatment against the microbes and to the tissue.

The present invention relates to Animals with mineral deficiencies become viable to pathogen attack. An improved method of treating mineral deficiencies is therefore desired. This invention is employing bioavailable minerals in a liquid complex that are pharmaceutically acceptable carrier including water. The composition for use in the method may include other supporting animal nutrients such as botanical extracts, animal hormones, vitamins, and mineral supplements necessary for animal health.

The present invention relates to Animals with mineral deficiencies become viable to pathogen attack. An improved method of treating mineral deficiencies is therefore desired. This invention is employing bioavailable minerals in a liquid complex that are pharmaceutically acceptable carrier including water. The composition for use in the method may include other supporting animal nutrients such as botanical extracts, animal hormones, vitamins, and mineral supplements necessary for animal health.

A nanoparticle, which has a metal oxide core and a cerium shell is provided. The weight ratio of the cerium within the shell to the metal oxide in the core is at least 1%. Additionally a method for delivering a ligand into a cell with the nanoparticle is provided. Processes for making the nanoparticle which include: sonicating an aqueous composition containing Ceric Ammonium Nitrate and a prefabricated nano particle suspension; and (b) adding a polycationic polymer to the mixture (for NP surface functionalization), are also described.

A nanoparticle, which has a metal oxide core and a cerium shell is provided. The weight ratio of the cerium within the shell to the metal oxide in the core is at least 1%. Additionally a method for delivering a ligand into a cell with the nanoparticle is provided. Processes for making the nanoparticle which include: sonicating an aqueous composition containing Ceric Ammonium Nitrate and a prefabricated nano particle suspension; and (b) adding a polycationic polymer to the mixture (for NP surface functionalization), are also described.

Disclosed is a self-assembled complex containing copper ions, including: copper ions; and one or more ligands, in which the ligands and the copper ions are reversibly self-assembled or self-degraded, and when there are a plurality of types of ligands or a plurality of ligands, the shape of the self-assembled complex is formed differently depending on the blending ratio of the ligands.

Disclosed is a self-assembled complex containing copper ions, including: copper ions; and one or more ligands, in which the ligands and the copper ions are reversibly self-assembled or self-degraded, and when there are a plurality of types of ligands or a plurality of ligands, the shape of the self-assembled complex is formed differently depending on the blending ratio of the ligands.

Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.